Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E

Fig. 1

Association of serum periostin and TNC levels with asthma severity and T-helper cell type 2 (Th2)-related variables. a Serum periostin levels (ng/mL); and b serum TNC levels (ng/mL). Mild to moderate asthma was defined as well-controlled asthma requiring GINA treatment steps 1–3. Severe asthma was defined as asthma requiring GINA treatment steps 4/5 and as uncontrolled asthma despite the treatment. *P < 0.05, mild to moderate versus severe asthma, Th2-low versus Th2-high, serum immunoglobulin E (IgE) ≤ 100 versus IgE > 100, peripheral blood eosinophil count (EOS) < 140 versus EOS ≥ 140, fractional exhaled nitric oxide (FeNO) < 50 versus FeNO ≥ 50. Bars indicate median values

Back to article page